HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The peptide-based vaccine induces a t cell-dependent response
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
Subscribe To Our Newsletter & Stay Updated